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Abstract
Objective—HIV-positive pregnant women are at heightened risk of becoming lost to follow-up
(LTFU) from HIV care. We examined LTFU before and after delivery among pregnant women
newly-diagnosed with HIV.
Methods—Observational cohort study of all pregnant women ≥18 years (N=300) testing HIV-
positive for the first time at their first ANC visit between January–June 2010, at a primary
healthcare clinic in Johannesburg, South Africa. Women (n=27) whose delivery date could not be
determined were excluded.
Results—Median (IQR) gestation at HIV testing was 26 weeks (21–30). 98.0% received AZT
prophylaxis, usually started at the first ANC visit. Of 139 (51.3%) patients who were ART-
eligible, 66.9% (95%CI 58.8–74.3%) initiated ART prior to delivery; median (IQR) ART duration
pre-delivery was 9.5 weeks (5.1–14.2). Among ART-eligible patients, 40.5% (32.3–49.0%) were
cumulatively retained through six months on ART. Of those ART-ineligible at HIV testing, only
22.6% (95%CI 15.9–30.6%) completed CD4 staging and returned for a repeat CD4 test after
delivery. LTFU (≥1 month late for last scheduled visit) before delivery was 20.5% (95%CI 16.0–
25.6%) and, among those still in care, 47.9% (95%CI 41.2–54.6%) within six months after
delivery. Overall, 57.5% (95%CI 51.6–63.3%) were lost between HIV testing and six months
post-delivery.
Conclusions—Our findings highlight the challenge of continuity of care among HIV-positive
pregnant women attending antenatal services, particularly those ineligible for ART.
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South Africa has a national antenatal HIV prevalence of 30.2% (Republic of South Africa
Department of Health 2010a) and more people living with HIV than any other country in the
world (UNAIDS 2010). In an ongoing effort to improve care for pregnant women with HIV
and to prevent mother-to-child transmission (PMTCT), South Africa’s 2010 HIV treatment
guidelines called for lifelong ART to be initiated for all pregnant women with a CD4 value
≤350 cells/µl (Republic of South Africa Department of Health 2010b) and PMTCT
guidelines mandated AZT prophylaxis from 14 weeks of pregnancy (Republic of South
Africa Department of Health 2010c). However, implementation of these guidelines remains
inadequate, with pregnant women in South Africa commonly presenting for their first ANC
visit well into their second trimester or later, delaying HIV diagnosis, AZT prophylaxis and
lifelong ART initiation (Black et al. 2008; Hoffman et al. 2010; Stinson et al. 2010).
In addition to late presentation for ANC services, some studies suggest that pregnant women
have poorer retention in HIV care than men and non-pregnant women (Kaplan et al. 2008;
Wang et al. 2011). Retention in HIV care is paramount, as HIV-positive patients require
routine management and daily adherence to ART once initiated (Republic of South Africa
Department of Health 2010d); mortality is high among patients who drop out of ART
programs (Brinkhof et al. 2009; Fox et al. 2010), and HIV/AIDS contributes to nearly half
(43.7%) of maternal deaths in South Africa, far overshadowing deaths due to other obstetric
complications such as hemorrhage or sepsis (National Committee on Confidential Enquiries
into Maternal Deaths 2008). An analysis of nearly 30,000 women initiating antiretroviral
therapy (ART) in South Africa found loss was 54% higher in pregnant than in non-pregnant
women (aHR 1.54; 95%CI 1.38–1.72), despite lower mortality (Myer et al. 2012a). The
reasons for these differences are still being identified, and may include lower rates of
immunosuppression and a lack of perception of need for treatment (Wang et al. 2011;
Solarin & Black 2012), heavier financial burden (Wang et al. 2011), travel or relocation
during pregnancy (Hoffman et al. 2010; Wang et al. 2011; Ferguson et al. 2012a), and
stigma (Hoffman et al. 2010; Ferguson et al. 2012b; Thorsen et al. 2008). In South Africa,
antenatal coverage is widespread and nearly all births occur in healthcare facilities (Shisana
et al. 2009), but there is still great difficulty in ensuring an unbroken continuum of HIV care
between antenatal care at a primary health clinic (PHC), labor and delivery at a hospital, and
postnatal care and ongoing HIV care returning at the PHC.
To date, investigations of retention in HIV care among pregnant women have provided an
estimate of loss to follow-up between specific milestones, such as HIV testing to ART
initiation (Stinson et al. 2010; Kaplan et al. 2008; Ferguson et al. 2012a), or ART initiation
to between 6 months and 3 years on treatment (Kaplan et al. 2008; Wang et al. 2011; Myer
et al. 2012a), without evaluating the impact of delivery on loss. While studies from the US
demonstrate ART adherence often declines in the postpartum period compared to during
pregnancy (Mellins et al. 2008; Ickovics et al. 2002; Tedaldi et al. 2002; Turner et al. 2000),
few studies have documented postpartum attendance in HIV care in sub-Saharan Africa in
routine clinic settings (Nassali et al. 2009). We hypothesize loss to follow-up may differ
before and after delivery given that women’s motivations for seeking care may change
during these time periods. This analysis of data from a cohort of newly-diagnosed HIV-
positive pregnant women examines loss to follow-up through early stages of HIV care to
better understand how loss to follow-up is influenced by delivery.
Methods
This study was conducted at Witkoppen Health and Welfare Centre (“Witkoppen”), a busy
facility (8500 clinic visits per month) providing primary healthcare services to formal and
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informal settlements in northern Johannesburg, South Africa. Between January and June
2010, 300 pregnant women (≥18 years) tested HIV-positive for the first time at their first
ANC visit at Witkoppen. We conducted a retrospective cohort study through file review to
assess attrition from pre-ART and on-ART care up to a minimum of 12 months after testing
HIV-positive.
HIV Care
At Witkoppen, HIV care is integrated with antenatal care for pregnant women, with
assessment for and initiation of ART occurring within ANC, and all documentation
contained within a single clinic file per patient. In early 2010, Witkoppen began initiating all
adult patients with CD4 ≤350 cells/µl onto ART, one year prior to national guidelines calling
for this approach. We confirmed ART eligibility at the time of HIV testing for each subject
through file review. During the time when the study was conducted, CD4 testing was
initiated at the same facility immediately following an HIV-positive test result, with a visit
scheduled two weeks later to receive the CD4 results. For ART eligible patients, an ART
initiation visit was scheduled two to four weeks after receiving the CD4 results. Patients
who wish to transfer facilities receive a referral letter and the file is noted accordingly.
Antenatal and Postnatal Care
Witkoppen offers antenatal and postnatal care, HIV testing and treatment on-site, as well as
other primary healthcare and social welfare services. HIV testing at Witkoppen occurs
during a woman’s first ANC visit and all HIV-positive pregnant women are given twice-
daily zidovudine (AZT) starting at 14 weeks gestation, as called for in PMTCT guidelines
(Republic of South Africa Department of Health 2010c). All women who receive antenatal
care at Witkoppen are designated to deliver at Hillbrow Hospital in central Johannesburg
(32.5 km from Witkoppen) or, if considered high-risk, at Charlotte Maxeke Johannesburg
Academic Hospital (28.9 km). At the hospital, women not yet on lifelong ART are given
intrapartum single-dose nevirapine and three-hourly AZT, as well as postpartum single-dose
tenofovir with emtricitabine for PMTCT. Newborns also start a six-week course of
nevirapine syrup from birth (Republic of South Africa Department of Health 2010c). The
hospitals do not routinely report delivery information back to Witkoppen. After delivery,
ANC patients return for postnatal care and HIV treatment services at Witkoppen for ten
weeks and then resume general adult care, all within the same facility and using the same
clinic file. Mothers and infants make three postnatal care visits together: 3–7 days after
delivery; six weeks after delivery for an infant polymerase chain reaction (PCR) HIV test;
and 10 weeks after delivery for infant HIV PCR results. Women previously ineligible for
ART should have a repeat CD4 at the six-week postpartum visit.
Timing of delivery
Data on gestational age at HIV testing based on last menstrual period were available in most
(88.3%) patient files, while date of delivery was available in patient files for 39.7% of
women. Thus, we determined a delivery date for 91% of women using either the actual date
or an estimation assuming 40 weeks gestation. Women with no calculated delivery date
(n=27, 9.0%) were excluded, leaving an analytic sample size of 273.
Statistical Methods
Patient characteristics are described using proportions and 95% confidence intervals
(95%CI) for categorical variables, and medians and interquartile ranges (IQR) for
continuous variables. We examine retention among pregnant women in two ways. First, we
report retention through several stages of pre- and post-ART care within the antenatal and
postnatal periods using counts and proportions with 95%CI. The first stage for all patients is
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completing CD4 staging, including results notification, prior to delivery. For the ART-
eligible, subsequent stages include ART initiation before or after delivery, completing a
clinic visit after delivery, and six months retention on ART. For ART-ineligible patients,
subsequent stages include returning for a clinic visit after delivery and receiving a repeat
CD4 test after delivery. A diagram of these stages is presented in Figure 1. Retention is
defined as completing each stage at Witkoppen and is determined using clinic visit data.
Patients who transfer are noted and removed from the analysis at the start of the stage in
which they transferred. Cumulative retention analyses exclude patients who transferred
during the antenatal (n=6) and postnatal (n=10) periods.
Second, we use time-to-event analysis to assess loss to follow-up before and after delivery
by estimating person-time in the antenatal and postnatal periods. Loss to follow-up is
defined as not returning to the clinic within a minimum of one month after the last scheduled
visit. For the antenatal period, person-time began accruing at testing HIV-positive and ended
at the first of the following three events: (1) delivery, (2) loss to follow-up or (3) transfer to
another facility prior to delivery. For women remaining in care at the beginning of the
postnatal period, person-time began accruing at delivery and ended at the earliest of: (1) six
months after delivery; (2) loss to follow-up; or (3) transfer after delivery. No deaths were
reported during the antenatal and postnatal time periods studied, so these represent all
possible known outcomes. After confirming proportional hazards using Schoenfeld
residuals, we examined predictors of loss within the antenatal and postnatal periods using
Cox proportional hazard regression, adjusting for covariates based on prior knowledge and
change-in-estimate evaluation, and report adjusted hazard ratios (aHR) and 95%CI.
Ethical approval for this study was granted by the Human Research Ethics Committee of the
University of the Witwatersrand and exemption was given by the Public Health-Nursing
IRB at the Office of Human Research Ethics at the University of North Carolina at Chapel
Hill.
Results
Clinical and demographic characteristics at HIV testing of the 273 pregnant women are
summarized in Table 1. The median (IQR) age at the first ANC visit was 27 years (24–31)
and the median CD4 count at the time of HIV testing was 357 cells/µl (238–500). Overall,
almost half of the cohort (44.7%) was born outside of South Africa, most notably in
Zimbabwe (89.3% of those foreign-born).
The median (IQR) gestational age at first ANC visit was 26 weeks (21–30) and the median
(IQR) time from HIV testing to delivery was 3.1 months (2.1–4.1). AZT monotherapy as
part of PMTCT was almost universally implemented. During pregnancy 98.0% received at
least one 30-day supply of AZT, all but one of whom (99.7%) started AZT on the day of
testing HIV-positive.
Retention during antenatal care
Figure 1 shows retention of pregnant women through early HIV care, contingent on
completing earlier stages. Roughly half of all women were ART-eligible at the time of
testing; median (IQR) CD4 at HIV testing was 244 cells/µl (171–299) among ART-eligible
and 500 cells/µl (420–599) among ART-ineligible women. Completing CD4 staging prior to
delivery was high at 84.9% (95%CI: 80.2–88.8%) overall, and varied little by ART
eligibility (87.1% vs. 82.7%). Of those who were ART-eligible and who completed CD4
staging prior to delivery (n=115), most (80.9%; 95%CI: 72.9–87.3%) went on to initiate
lifelong ART prior to delivery. These women spent a median (IQR) of 27 days (17–41.5)
from HIV testing to ART initiation and a median (IQR) 9.5 weeks (5.1–14.2) on ART prior
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to delivery. Of the remaining 22 ART-eligible women who completed CD4 staging but did
not initiate ART prior to delivery, most (n=18, 81.8%) never returned for ART initiation,
one returned but left before initiation, one required further counseling, one refused ART,
and one completed the initiation visit but was rescheduled to return for initiation a week
later and did not return. Of all 139 ART-eligible women, 66.9% (95%CI: 58.8–74.3%)
initiated treatment prior to delivery.
Retention after delivery
The proportion of patients returning for at least one visit after delivery was highest among
those who were eligible for ART and initiated treatment prior to delivery (n=90) at 76.7%
(95%CI: 67.1–84.5%) with most of these women (82.8%; 95%CI: 72.1–90.6%) retained in
ART care for at least six months. Though the numbers of women who completed CD4
staging and were eligible for but did not initiate ART were small (n=22), only 31.8%
(95%CI: 15.1–53.1%) returned at any point after delivery, and less than half of those who
did (42.9%; 95%CI: 12.3–78.4%) initiated ART within six months of delivery. The picture
was much different for those ineligible for ART at the time of testing positive. Among those
ART-ineligible who completed CD4 staging (n=112), less than half (49.1%, 95%CI: 39.9–
58.3%) returned for any visits after delivery. Of these 50 women, only half (52.0%, 95%CI:
38.2–65.5%) received a repeat CD4 count after delivery.
Cumulative retention in HIV care
Figure 2 shows cumulative retention for ART-eligible women from HIV testing through
delivery and six months on ART as well as for ART-ineligible women through a post-
delivery repeat CD4 count. Cumulatively, less than half (40.5%, 95%CI: 32.3–49.0%) of
ART-eligible patients who tested HIV-positive during pregnancy completed CD4 staging,
initiated ART prior to delivery, returned after delivery and completed six months on ART.
Cumulative retention was even lower among those ineligible for ART at the time of HIV
testing: only 22.6% (95%CI: 15.9–30.6%) of patients ineligible for ART continued in care
to the point of a repeat CD4 count after delivery.
The median (IQR) person-time contributed in the antenatal period was 2.8 months (1.7–3.9)
and 4.5 months (1.5–6.0) in the postnatal period. Using time-to-event analysis and analyzing
all women regardless of ART eligibility at the time of testing, 20.5% (95%CI: 16.0–25.6%)
of women were lost to follow-up prior to delivery. Among women in care at delivery, 47.9%
(95%CI: 41.2–54.6%) were lost within six months after delivery, for a cumulative loss to
follow-up of 57.5% (95%CI: 51.6–63.3%).
Table 2 presents the results of multivariate analysis of factors associated with loss within the
antenatal and postnatal time periods. Presenting late for the first ANC visit (after 20 weeks
gestation) was associated with twice the likelihood of loss prior to delivery after adjusting
for age, initial CD4 count and nationality (aHR 2.00; 95%CI 1.00, 4.02) but late presentation
was not associated with loss during the postnatal period (aHR 1.09; 95%CI 0.65–1.83). ART
ineligibility at the time of HIV testing based on a CD4 count >350 cells/µl was strongly
associated with loss to follow-up following delivery (aHR 3.30; 95%CI: 1.95–5.58), while
pregnant women age 30 years and older were less likely to be lost after delivery (aHR 0.49;
95%CI: 0.30–0.81). Our results suggest that women born outside of South Africa may be
more likely to be lost after delivery (aHR 1.36; 95%CI: 0.90–2.06) than women born in
South Africa.
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Pregnant women diagnosed with HIV during antenatal care require effective care
interventions to ensure the prompt initiation of PMTCT and ART, but also must be linked to
HIV care that is sustainable beyond the point of delivery. We found that overall loss to
follow-up within 13 months of HIV testing among pregnant women recently diagnosed with
HIV was staggeringly high at 57.5% (95%CI: 51.6–63.3%). Unlike studies that begin
reporting loss to follow-up at ART initiation, our findings span the period from testing HIV-
positive through both the pre-ART and early post-ART periods, periods of high attrition.
Patients who initiate ART have already successfully been retained through several visits,
and thus, may be more inclined to continue in care. Few reports exist of retention of all
patients – both ART eligible and ineligible. Our loss to follow-up proportion, which includes
this early loss, is much higher than the 12%–32% among pregnant women after six months
to three years on ART reported elsewhere which only focuses on the on-treatment period
(Kaplan et al. 2008; Wang et al. 2011; Myer et al. 2012a).
Our analysis also suggests that the focus on cumulative loss to follow-up among pregnant
women is missing important trends over time with implications for when to intervene. Loss
to follow-up prior to delivery was much lower than after delivery (20.5% vs. 47.9%). The
antenatal period is a time of reasonable compliance with HIV care, likely because women
are already attending care for another reason for which they have motivation to continue.
Our results suggest many women are not returning to the PHC after delivery. Among HIV-
positive pregnant women, the challenge is ensuring HIV care extends beyond the period of
pregnancy and continues for the lifetime of the mother. In South Africa, infants are to
accompany their mothers to the first three postnatal care visits, so failure to attend these
visits also suggests a failure to link infants to postnatal care, including PCR testing for HIV
and immunizations.
In addition to a high rate of loss to follow-up, we also found that pregnant women presented
for their first ANC visit and HIV testing well after the recommended gestational age of 14
weeks for AZT initiation. The median gestational age at HIV testing of 26 weeks in our
study matched that found by Stinson et al. (2010), and represents delayed PMTCT efforts.
Half of the pregnant patients in our cohort were ART-eligible at their first ANC visit, yet
despite the overall trend of late presentation, 66.9% (95%CI: 58.8–74.3%) of those eligible
initiated ART prior to delivery. The median time from first visit to ART initiation of 27 days
indicates that patients are being initiated promptly after the first visit, but as the median time
on ART is 9.5 weeks, they are not presenting early enough to obtain maximal effectiveness
of ART for PMTCT, which is reached around 13–15 weeks duration prior to delivery
(Chibwesha et al. 2011; Patel et al. 2007). The median duration on ART prior to delivery in
our study is consistent with findings of 7.6–10.7 weeks in other studies in South Africa
(Black et al. 2008; Hoffman et al. 2010; Stinson et al. 2010; Fitzgerald et al. 2010).
Additionally, nearly one-third (31.1%, 95%CI 25.7–41.2%) of ART-eligible women should
have initiated before delivery but did not. Recognition of the problem of late presentation to
ANC care and its impact on delayed ART initiation, as well as poor linkage to care prior to
ART, has spurred interest in rapid or same-day ART initiation among pregnant women
using point-of-care CD4 testing (Myer et al. 2012b).
South African ANC patients receive a government-mandated ANC card at their first ANC
visit, and must present it at the hospital labor ward prior to delivery. There has been
speculation that women only attend one ANC visit to get this card but do not return for
additional care. Our data do not support this idea. Among pregnant women in our cohort,
15.1% failed to complete CD4 notification (i.e. attended only one clinic visit), which is half
the proportion (30.2%) of non-pregnant adults who did not complete CD4 staging during
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this same period (Clouse et al. 2013). Our finding of sufficient linkage to care among
pregnant women is consistent with that of Kranzer et al. (2010), who found CD4 completion
was highest among antenatal care patients in Cape Town when compared to patients of other
clinic services. This suggests that many women are making repeat visits while pregnant but
many then stop after delivery.
In our study women who presented late for their first ANC visit (>20 weeks gestation) were
twice as likely to be lost prior to delivery (aHR 2.00, 95%CI 1.00–4.02), underscoring the
difficulty of retaining patients who are initially slow to seek care. Three South Africa-based
studies identified fear of HIV testing/diagnosis, confusion over pregnancy status, transport
limitations, lack of perceived benefit, and clinic booking delays as common reasons for late
presentation among ANC patients (Solarin & Black 2012; Myer & Harrison 2003; Laher et
al. 2012), highlighting the multi-level barriers that can prevent timely access to and retention
in care among pregnant women. Patients with higher CD4 counts (>350 cells/µl) who were
ineligible for ART were more likely to be lost postpartum (aHR 3.30; 95%CI 1.95–5.58),
emphasizing the importance of retention during pre-ART care. South Africa’s PMTCT
guidelines call for repeat CD4 testing after delivery, but only 22.6% of ART-ineligible
women received a repeat CD4 count. Witkoppen has a very high proportion of patients born
outside of South Africa, as is now common in PHCs throughout Johannesburg (Faal et al.
2011; City of Johannesburg 2011). These patients may be at greater risk of loss to follow-up
after delivery (aHR 1.36; 95%CI 0.90–2.06), likely because of frequent mobility among this
group.
Our findings must be considered in light of the study’s limitations. First, we do not know
why women ceased care at Witkoppen. Under half (45.2%) of the women who were lost
received at least one follow-up phone call. We reviewed the files of 84 pregnant patients
who were lost to follow-up whom the clinic had made at least one attempt to contact. Over
half (52.3%) were unreachable because their cell phone was off or out of service and 20.2%
were found to have moved out of the area, usually outside Johannesburg’s Gauteng
Province. This may indicate that women return to rural homes (Hoffman et al. 2010; Wang
et al. 2011; Ferguson et al. 2012a) – whether in South Africa or a neighboring country –
either immediately prior to or after birth. While migration around delivery is typically short-
term, it disrupts the continuity of care, which likely impairs adherence to ART. Further
research is needed to better understand pregnancy-associated migration and its impact on
maternal and infant health.
Second, we do not know if patients who drop out of care at Witkoppen continue in care at
other facilities, perhaps in a rural facility or outside South Africa, except for those who
request a formal transfer. While this is a limitation shared by most studies of loss to follow-
up, it is important to note that loss to follow-up in this study reflects ceasing care at one
clinic only, but one that was selected for study due to close integration of antenatal care,
postnatal care and HIV services. We also cannot link to hospital data to confirm delivery,
nor do we have data on infant clinic visits or outcomes. More research is needed into ways
to improve linkages across treatment sites and ways to improve patient movement between
sites (e.g. providing sufficient supply of antiretrovirals).
Finally, our study data, which were collected retrospectively, were limited to those routinely
collected in the patient files, but with very few missing data. Our findings regarding timing
of first ANC visit and linkage to care among ANC patients are consistent with previously
reported studies from other regions of South Africa (Stinson et al. 2010; Kranzer et al.
2010), suggesting that our results are generalizable to other clinics throughout South Africa.
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Further research that examines pregnant women’s reasons for dropping out of care,
interventions to reduce ante- and postnatal attrition, and follow-up studies to confirm
linkages to care among new mothers, is needed urgently. Case management interventions to
improve linkages to HIV care have demonstrated success in the US (Craw et al. 2008;
Gardner et al. 2005) and research on implementation of this type of intervention in the
southern African setting is warranted.
Our study highlights much room for improvement in the provision of HIV care of pregnant
women. We found that pregnant women presented late for their first ANC visit, initiated
ART too late to achieve maximal PMTCT effectiveness, and had high rates of drop out
around the time of delivery. Pregnant women likely have different motivation for attending
healthcare services than non-pregnant adults, and likewise, different reasons why they may
become lost. Efforts must be increased to better understand the intentions of pregnant
women for seeking healthcare after delivery, understanding their motivations for ceasing
HIV care, and improve linkages to care after delivery.
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Table 1
Characteristics of the study participants (N=273)
Patient characteristic
Continuous variables, median (IQR)
Age at HIV testing 27 (24–31)
First CD4 value (cells/µl) 357 (238–500)
Weeks of gestation at first ANC visit 26 (21–30)
Categorical variables, n (%)
Age at HIV testing
  18–24 years 78 (28.6%)
  25–29 years 98 (35.9%)
  30 years and older 97 (35.5%)
First CD4 value
  <50 cells/µl 4 (1.5%)
  50–199 cells/µl 48 (17.6%)
  200–350 cells/µl 83 (30.4%)
  >350 cells/µl 136 (49.8%)
  Missing 2 (0.7%)
Nationality
  Born in South Africa 143 (52.4%)
  Born outside of South Africa 122 (44.7%)
  Missing 8 (2.9%)
Employment status
  Employed 97 (35.5%)
  Not employed 167 (61.2%)
  Missing 9 (3.3%)
Gestation at first ANC visit
  ≤20 weeks 59 (21.6%)
  >20 weeks 214 (78.4%)
IQR, interquartile range
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